Retatrutide Results Propel Lilly Toward 2027 FDA Filing
Retatrutide results show strong Phase 3 weight loss and a planned Q1 2027 BLA, sharpening investor positioning and flows into Lilly's obesity franchise.
KEY TAKEAWAYS
- Retatrutide showed 20.8% to 22.6% average weight loss at 80 weeks in two Phase 3 trials.
- Lilly plans to submit a biologics license application to the FDA in Q1 2027.
- Cardiovascular-event analysis in the CVD trial did not show a statistically significant reduction.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly (LLY) said in a press release on July 23, 2026, that retatrutide results from two Phase 3 trials showed marked weight loss at 80 weeks and that the company plans to submit a biologics license application to the FDA in Q1 2027.
Phase 3 Efficacy Results
Eli Lilly’s investigational obesity drug retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, delivered positive topline results in two 80-week Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, both meeting their primary endpoints. In TRIUMPH-2, which enrolled adults with obesity or overweight and type 2 diabetes, the highest-dose group lost an average of 20.8% of body weight, about 49.6 pounds, and showed an A1C reduction of 1.6%. TRIUMPH-3, conducted in adults with severe obesity and established cardiovascular disease, recorded a 22.6% average weight loss, roughly 55.8 pounds, in the highest-dose cohort.
Regulatory Path and Context
Lilly said it plans to submit a biologics license application (BLA) to the FDA in the first quarter of 2027. Retatrutide remains investigational and is not yet approved. The company is completing manufacturing and chemistry, manufacturing, and controls (CMC) work as it prepares the regulatory package.
Secondary analysis of the cardiovascular-disease trial showed no statistically significant reduction in major cardiovascular events compared with placebo, leaving the question of cardiovascular benefit unresolved. The positive weight-loss results extend Lilly’s obesity pipeline and add momentum to its next-generation obesity franchise.
